Efficacy and Safety of Chinese Herbal Formula Granules in Treating Chronic Kidney Disease Stage 3: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Table 8

Change from baseline in serum creatinine over the 24-week follow-up period in the CKD stage 3a subgroup.

Time	Treatment group	Control group	Effect	F value	value
Pretreatment (μmol/L)	130.27 ± 15.79	132.46 ± 21.82	Time effect	0.40	0.8511
Week 4 (μmol/L)	120.93 ± 17.10	133.80 ± 23.82	Difference between groups	25.42	<0.0001
Week 8 (μmol/L)	117.54 ± 19.61	136.63 ± 27.40
Week 12 (μmol/L)	117.74 ± 18.09	134.98 ± 32.59
Week 16 (μmol/L)	116.43 ± 18.70	136.87 ± 35.06
Week 20 (μmol/L)	116.13 ± 19.25	136.18 ± 30.23
Week 24 (μmol/L)	115.11 ± 19.18	136.21 ± 39.45